These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32882421)

  • 1. Dissolution testing of modified release products with biorelevant media: An OrBiTo ring study using the USP apparatus III and IV.
    Reppas C; Vrettos NN; Dressman J; Andreas CJ; Miyaji Y; Brown J; Etherson K; Hanley S; Karkossa F; Karlsson E; Klein S; Maier GM; McAllister M; Mistry N; Rosenblatt K; Schäfer KJ; Smith KL; Tomaszewska I; Williams J; Winge F; Vertzoni M
    Eur J Pharm Biopharm; 2020 Nov; 156():40-49. PubMed ID: 32882421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
    Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
    Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.
    Andreas CJ; Tomaszewska I; Muenster U; van der Mey D; Mueck W; Dressman JB
    Eur J Pharm Biopharm; 2016 Aug; 105():193-202. PubMed ID: 27322002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
    Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic investigation of the negative food effect of modified release zolpidem.
    Andreas CJ; Pepin X; Markopoulos C; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Sci; 2017 May; 102():284-298. PubMed ID: 28286289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development.
    Fang JB; Robertson VK; Rawat A; Flick T; Tang ZJ; Cauchon NS; McElvain JS
    Mol Pharm; 2010 Oct; 7(5):1466-77. PubMed ID: 20701327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197.
    Schilderink R; Protopappa M; Fleth-James J; Vertzoni M; Schaefer K; Havenaar R; Kulla I; Metzger M; Reppas C
    Eur J Pharm Biopharm; 2020 Apr; 149():154-162. PubMed ID: 32057905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation.
    Berben P; Ashworth L; Beato S; Bevernage J; Bruel JL; Butler J; Dressman J; Schäfer K; Hutchins P; Klumpp L; Mann J; Nicolai J; Ojala K; Patel S; Powell S; Rosenblatt K; Tomaszewska I; Williams J; Augustijns P
    Eur J Pharm Biopharm; 2019 Jul; 140():141-148. PubMed ID: 31051249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution profiles of BCS class II drugs generated by the gastrointestinal simulator alpha has an edge over the compendial USP II method.
    Naing MD; Tsume Y
    Eur J Pharm Biopharm; 2024 Oct; 203():114436. PubMed ID: 39111581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Approach for the Application of USP Apparatus 3 in Dissolution Tests: Case Studies of Three Antihypertensive Immediate-Release Tablets.
    Espíndola B; Bortolon FF; Pinto JMO; Pezzini BR; Stulzer HK
    AAPS PharmSciTech; 2018 Oct; 19(7):2866-2874. PubMed ID: 29934804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological Considerations and In Vitro Strategies for Evaluating the Influence of Food on Drug Release from Extended-Release Formulations.
    Koziolek M; Kostewicz E; Vertzoni M
    AAPS PharmSciTech; 2018 Oct; 19(7):2885-2897. PubMed ID: 30155808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of Biowaivers for Immediate Release Formulations Containing BCS III Drugs, Acyclovir, Atenolol, and Ciprofloxacin Hydrochloride, Using Dissolution Testing.
    Reddy NH; Patnala S; Kanfer I
    AAPS PharmSciTech; 2017 Feb; 18(2):424-431. PubMed ID: 27038483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media.
    Nurhikmah W; Sumirtapura YC; Pamudji JS
    Sci Pharm; 2016; 84(1):181-90. PubMed ID: 27110508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanism of solifenacin release from a pH-responsive ion-complex oral suspension in the fasted upper gastrointestinal lumen.
    Yamamoto Y; Kumagai H; Haneda M; Vertzoni M; Ouwerkerk N; Murayama D; Katakawa Y; Motonaga K; Reppas C; Tajiri T
    Eur J Pharm Sci; 2020 Jan; 142():105107. PubMed ID: 31669386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dissolution methods for drug release testing of Long-Acting injectables.
    Malavia N; Bao Q; Burgess DJ
    Int J Pharm; 2024 Oct; 664():124634. PubMed ID: 39182741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharmaceutical implications of excipient variability on drug dissolution from immediate release products.
    Zarmpi P; Flanagan T; Meehan E; Mann J; Østergaard J; Fotaki N
    Eur J Pharm Biopharm; 2020 Sep; 154():195-209. PubMed ID: 32681966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hierarchical Mass Transfer Analysis of Drug Particle Dissolution, Highlighting the Hydrodynamics, pH, Particle Size, and Buffer Effects for the Dissolution of Ionizable and Nonionizable Drugs in a Compendial Dissolution Vessel.
    Salehi N; Al-Gousous J; Mudie DM; Amidon GL; Ziff RM; Amidon GE
    Mol Pharm; 2020 Oct; 17(10):3870-3884. PubMed ID: 32886520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.